Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, China.
Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
J Gastroenterol Hepatol. 2020 Dec;35(12):2256-2263. doi: 10.1111/jgh.15122. Epub 2020 Jun 23.
Fully covered self-expandable metal stents (FCSEMSs) have been increasingly used in the management of benign or malignant biliary disorders. However, the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) with transpapillary placement of the FCSEMS remains controversial. This study therefore aimed to investigate the risk of PEP in patients who received FCSEMS implantation.
In total, 602 patients who underwent endoscopic transpapillary FCSEMS placement at five Chinese medical centers, between 2011 and 2018, were included in this retrospective study. Patients who were younger than 18 years and with stent placement above the papilla were excluded from the study. PEP and the risk factors were reviewed.
PEP occurred in 56 (9.3%) patients, and eight (1.3%) of them experienced moderate-to-severe PEP. The incidence of PEP rose to 14.6% (51/349) when patients had no pancreatic duct (PD) dilation, and even to 18.6% if no prophylactic approaches were adopted. Prophylactic PD stenting showed better efficacy in reducing the incidence of PEP than did rectal use of indomethacin (3.5% vs 10.8%, P = 0.023). Multivariate logistic regression revealed that difficult cannulation (OR 2.837, 95% CI 1.245-6.465, P = 0.013), PD dilation (OR 0.145, 95% CI 0.05-0.422, P < 0.001), and PD stenting (OR 0.247, 95% CI 0.089-0.686, P = 0.007) were significantly associated with PEP risk. Post-procedure cholecystitis was found in 4.0% of patients.
The risk of post-procedure pancreatitis is modestly increased in patients receiving transpapillary FCSEMS placement, particularly when there is absence of PD dilation. Thus, prophylactic pancreatic stenting is recommended in such a condition.
完全覆膜自膨式金属支架(FCSEMS)在治疗良性或恶性胆道疾病中的应用日益增多。然而,经内镜逆行胰胆管造影(ERCP)放置 FCSEMS 后发生胰腺炎(PEP)的风险仍存在争议。本研究旨在探讨接受 FCSEMS 植入的患者发生 PEP 的风险。
本回顾性研究纳入了 2011 年至 2018 年期间在中国五家医疗中心接受内镜经乳头 FCSEMS 放置的 602 例患者。研究排除了年龄小于 18 岁和支架放置在乳头上方的患者。回顾性分析了 PEP 及相关危险因素。
56 例(9.3%)患者发生了 PEP,其中 8 例(1.3%)为中重度 PEP。当患者无胰管(PD)扩张时,PEP 的发生率上升至 14.6%(51/349),如果不采取预防措施,甚至上升至 18.6%。预防性 PD 支架置入在降低 PEP 发生率方面优于直肠使用吲哚美辛(3.5% vs 10.8%,P=0.023)。多因素 logistic 回归分析显示,困难插管(OR 2.837,95%CI 1.245-6.465,P=0.013)、PD 扩张(OR 0.145,95%CI 0.05-0.422,P<0.001)和 PD 支架置入(OR 0.247,95%CI 0.089-0.686,P=0.007)与 PEP 风险显著相关。术后胆囊炎的发生率为 4.0%。
经内镜逆行胰胆管造影放置 FCSEMS 后胰腺炎的风险略有增加,尤其是在 PD 无扩张的情况下。因此,在这种情况下推荐预防性胰管支架置入。